455 related articles for article (PubMed ID: 31735731)
21. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
22. Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort.
Ochi Y; Kubo T; Baba Y; Sugiura K; Miyagawa K; Noguchi T; Hirota T; Hamada T; Yamasaki N; Kitaoka H
Circ J; 2022 Jun; 86(7):1121-1128. PubMed ID: 35599003
[TBL] [Abstract][Full Text] [Related]
23. Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.
Rozenbaum MH; Tran D; Bhambri R; Nativi-Nicolau J
Am J Cardiovasc Drugs; 2022 Jul; 22(4):445-450. PubMed ID: 35353352
[TBL] [Abstract][Full Text] [Related]
24. Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
Vong C; Boucher M; Riley S; Harnisch LO
Am J Cardiovasc Drugs; 2021 Sep; 21(5):535-543. PubMed ID: 33770392
[TBL] [Abstract][Full Text] [Related]
25. [Experience with tafamidis in a patient with transthyretin amyloidosis].
Nasonova SN; Zhirov IV; Magomedov MM; Saidova MA; Osmolovskaya YF; Tereschenko SN
Kardiologiia; 2020 Jan; 60(3):155-160. PubMed ID: 32375630
[TBL] [Abstract][Full Text] [Related]
26. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
27. Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
Li H; Rozenbaum M; Casey M; Sultan MB
Cardiology; 2022; 147(4):398-405. PubMed ID: 35853436
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
29. Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis.
Saro R; Allegro V; Merlo M; Dore F; Sinagra G; Porcari A
Heart Fail Clin; 2024 Jul; 20(3):343-352. PubMed ID: 38844305
[TBL] [Abstract][Full Text] [Related]
30. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
Grogan M; Davis MK; Crespo-Leiro MG; Sultan MB; Gundapaneni B; Stedile Angeli F; Hanna M
Eur J Heart Fail; 2024 Mar; 26(3):612-615. PubMed ID: 38439606
[TBL] [Abstract][Full Text] [Related]
31. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
32. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.
Kuyama N; Takashio S; Oguni T; Yamamoto M; Hirakawa K; Ishii M; Hanatani S; Oda S; Matsuzawa Y; Usuku H; Yamamoto E; Hirai T; Ueda M; Tsujita K
J Am Heart Assoc; 2024 May; 13(10):e034518. PubMed ID: 38761073
[TBL] [Abstract][Full Text] [Related]
33. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Sultan MB; Maurer MS
Future Cardiol; 2022 Mar; 18(3):165-172. PubMed ID: 34779246
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Future Cardiol; 2023 Jan; 19(1):7-17. PubMed ID: 36715498
[TBL] [Abstract][Full Text] [Related]
35. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
36. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
[TBL] [Abstract][Full Text] [Related]
37. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
[TBL] [Abstract][Full Text] [Related]
38. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
39. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
[TBL] [Abstract][Full Text] [Related]
40. What is this image? 2022 image 1 result: radiologic improvement of transthyretin cardiac amyloidosis after treatment with tafamidis.
Mekritthikrai R; Gomez-Valencia J; Malhotra S
J Nucl Cardiol; 2022 Aug; 29(4):1500-1502. PubMed ID: 35715715
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
